Description
Trastuzumab deruxtecan also known as fam-trastuzumab deruxtecan and sold under the brand name Enhertu, is a medication used for the treatment of adults with unresectable (unable to be removed with surgery) or metastatic (when cancer cells spread to other parts of the body) HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.
Trastuzumab deruxtecan is an antibody-drug conjugate that includes a human epidermal growth factor receptor 2 (HER2)-directed antibody trastuzumab and a topoisomerase I inhibitor conjugate deruxtecan (a derivative of exatecan). It was approved for use in the United States in December 2019.
Authorized Distributor / Supplier of Trastuzumab Deruxtecan –
ENHERTU 100mg per vial. Concentrate Solution for infusion.
South Delhi Pharma is Authorized Distributor / Supplier in India for Trastuzumab Deruxtecan –
ENHERTU 100mg per vial. Concentrate Solution for infusion. Trastuzumab Deruxtecan, sold under the brand name Enhertu®, is manufactured by Daiichi Sankyo, Inc. and AstraZeneca. It has been approved by the FDA. For pricing information on Enhertu® in India, please contact via phone or WhatsApp at +91-9891296838 or email at info@southdelhipharma.com. Enhertu® is supplied in form: Trastuzumab Deruxtecan – ENHERTU 100mg per vial. Concentrate Solution for infusion. It is available in various cities across India, including Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, and other cities in India.
References: